Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Repligen Corp (NQ: RGEN)
15.36 USD  -0.48 (-3.03%)
Streaming Delayed Price  /  Updated: 10:29 AM EDT, Apr 24, 2014  /  Add to My Watchlist      
(RGEN) Community Analysis from
April 24, 2014
Editor’s note: this column was originally published on Capital Essence’s CEM News. It’s being republished as a bonus for the loyal readers. For more information about subscribing to CEM News,...(read more)
(Jutia Group, 1/10/14)
[at Motley Fool] - Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect its top line for...(read more)
(, 2/27/11)
Repligen Corp (RGEN) has been settling near the bottom of the trading range on low volume.  It has formed a small head and shoulders pattern, but it seems to have relatively good support around...(read more)
Repligen (RGEN) Company Overview

There is no analysis for RGEN yet. But you can go to Wikinvest to help create one!

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here